Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
FICO Score - Teaching Note
Eades; Kenneth M.; Fairchild; Gregory B.; Maiden; Stephen E.Nota del Instructor DARDEN-F-1909TN-EFinanzasTeaching note for product F-1909Desde 0,00 €
-
FICO Score
Eades; Kenneth M.; Fairchild; Gregory B.; Maiden; Stephen E.Caso DARDEN-F-1909-EFinanzasThis case teaches students the importance of maintaining a strong FICO score by illustrating the consequences of paying bills late or not at all. The protagonist is David Molina; a waiter at a struggling Italian restaurant located down the block from where he lives. Money is tight for Molina right now—his limited income means he lives paycheck to paycheck. However; Molina knows things will be looking up for him soon because he recently accepted a...Desde 8,20 €
-
From Stuffing to Streamlining: Pharmaceutical Distribution
Thomas; Doug; Zhao; Hui; Maiden; Stephen E.; Yemen; GerryCaso DARDEN-F-1859-EFinanzasThis case uses the streamlining of pharmaceutical distribution to explore supply-chain coordination. For years; supply-chain inventory information had been opaque. Then in the early 2000s; pharmaceutical manufacturers and distributors were forced to shift from investment buying to inventory service agreements. Information sharing among channel partners regarding customer demand and inventories was believed to lead to better decision-making; impro...Desde 8,20 €
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCaso DARDEN-F-1715-EFinanzasThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Desde 8,20 €
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCaso DARDEN-F-1716-EFinanzasIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Desde 8,20 €